A recent study reveals that people who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional diet and exercise programs.
Research printed in a prominent health publication shows that while obese people often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing these treatments need to be aware of the potential of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to starting mass in about one and a half years.
Analyzing Therapies
The analysis, which reviewed dozens of trials involving over 9,000 of participants, compared the results of the injectable medications with older methods.
Researchers point out that people who lose weight through dieting usually have a slower weight regain—around 0.1 kg a month—after stopping.
The Reason for the Rapid Regain
Doctors suggest the mode of action of the jabs accounts for the amplified regain.
These medications mimic a natural hormone called GLP-1, which moderates appetite.
"Artificially providing the hormone concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in appetite is uncontrolled, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, given the high risk of weight regain, the treatment should be considered life-long.
This perspective is supported by drug manufacturers, who state that the results "underscore the chronic character of obesity," similar to managing diseases like diabetes.
Patient Testimonies
Users who have stopped the jabs describe a powerful resurgence of cravings.
"It was like something activating and you're instantly ravenous," described an individual.
The struggle is worsened if patients have not adopted permanent lifestyle or habit changes during treatment.
Significant Interest
Figures indicate that a significant number of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is more common among women than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while these medications are effective tools for weight loss, they are not a standalone cure and long-term success relies on combined lifestyle support.
